The United States will soon reach an important milestone in the COVID-19 pandemic: the official end of the federal public health emergency (PHE). According to the U.S. Department of Health and Human Services (HHS), the COVID-19 PHE will expire on May 11, 2023. This significant transition has been made possible, in part, by the biopharmaceutical industry’s continuing efforts to research, develop and manufacture safe, effective treatments and vaccines for COVID-19. The industry leveraged decades of research and investments into developing medical solutions to prevent and treat COVID-19 and remains committed to supporting innovation in this space.
